Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

South Valley University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Anosmia

Treatments: Drug: intranasal spray ivermectin

Study type: Interventional

Funder types: Other

Identifiers

NCT04951362

SVU MED CIT0 23 4 21 1 122

Details and patient eligibility

About

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Full description

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection

Enrollment: 117 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• post covid19 anosmia
• negative swab test for covid19

Exclusion criteria

• other types of anosmia ,
• no local or central other causes of anosmia
• still active covid 19 pateints ( positive swab test )

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

117 participants in 2 patient groups, including a placebo group

intranasal Ivermectin group

Active Comparator group

Description:

49 pateints with anosmia received ivermectin nanosuspension nasal spray

Treatment:

Drug: intranasal spray ivermectin

saline nasal spray

Placebo Comparator group

Description:

47 pateints with anosmia received saline nasal spray

Treatment:

Drug: intranasal spray ivermectin